HEATHER BAUGH: Open Payments
NPI 1649653668 · GLENDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,030 in 101 payments from 14 companies in 2025. Trend: 2023 $1,987 · 2024 $2,068 · 2025 $2,030
Food & beverage: $2,030
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 21 | $450 |
| ABBVIE INC. | 25 | $361 |
| Vanda Pharmaceuticals Inc. | 10 | $230 |
| Neurocrine BioSciences, Inc. | 6 | $226 |
| Lundbeck LLC | 10 | $189 |
| E.R. Squibb & Sons, L.L.C. | 4 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $93 |
| Axsome Therapeutics, Inc. | 5 | $88 |
| Alkermes, Inc. | 4 | $83 |
| Janssen Pharmaceuticals, Inc | 4 | $83 |
Products named: CAPLYTA, VRAYLAR, REXULTI, FANAPT, INGREZZA, COBENFY, TRINTELLIX, Auvelity.
Industry payments across AZ — which companies pay providers there.
